Representative before the EPO

Technology company logo thumb
no operation time available
4 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
4 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
7 offices
Technology Company

We have observed 20 EP applications James Michael Frederic Horgan has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11833150

QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS

IPC classification:
C07D 401/04, C07D 239/42, A01N 43/54
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
The patent has been granted
EP11836908

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

IPC classification:
A61K 31/445, A61K 31/40
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11851281

QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS

IPC classification:
A61K 31/498, C07D 241/36
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
The patent has been granted
EP11836900

METHODS FOR IDENTIFYING NOTCH-SPARING GAMMA SECRETASE INHIBITORS

IPC classification:
C12Q 1/37
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP11829799

GENERATION, CHARACTERIZATION AND USES THEREOF OF ANTI-HER3 ANTIBODIES

IPC classification:
A61K 39/395
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP12768642

pAVEC

IPC classification:
C12N 15/64, C12N 15/11, C07H 21/04
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12782391

BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS

IPC classification:
A61K 31/44, A01N 43/40, C07D 213/04
Applicant:
Merck Canada Inc.
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12786546

THERAPEUTIC ANTI-IGF1R COMBINATIONS

IPC classification:
A61K 39/395, C12P 21/08, C07K 16/28
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP12746556

USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY

IPC classification:
A61P 19/02, A61K 38/17, A61K 39/395, A61K 38/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11833005

USES OF MACROPHAGE MANNOSE RECEPTOR TO SCREEN COMPOUNDS AND USES OF THESE COMPOUNDS

IPC classification:
A61K 47/48, A01N 25/00, C07K 14/00, C07K 1/00, C07K 17/00, A61K 38/14
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION REQUESTED
EP12760995

AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES

IPC classification:
A61K 31/4162, C07D 487/04, A61P 35/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12780029

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

IPC classification:
A61K 31/44, A61K 31/427, C07D 417/14, C07D 401/02, A61P 35/00, A61P 19/02, A61P 11/06, A61P 11/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12782298

AMINOPYRIMIDINES AS SYK INHIBITORS

IPC classification:
A61K 31/506, A61K 31/505, A01N 43/54, C07D 417/14, C07D 417/12, A61P 35/00, A61P 11/06
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP12782164

PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS

IPC classification:
A61K 31/444, C07D 417/14, A61P 37/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP12763896

STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENTS

IPC classification:
A61K 39/395, A61K 39/00, A61K 9/19, C07K 16/28
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12789452

METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES

IPC classification:
C12P 21/00, C07K 16/42, C07K 16/40, C07K 16/28, C07K 16/24, C07K 16/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck Sharp & Dohme Ltd.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13180969

Beta-lactamase Inhibitors

IPC classification:
A61P 31/04, A61K 31/535, A61K 31/529, C07D 519/00, C07D 487/08, C07D 471/08
Applicant:
Merck Sharp & Dohme Corporation
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14838254

DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH

IPC classification:
C07D 239/28, A61K 31/505
Agent:
James Michael Frederic Horgan, Merck Sharp & Dohme Ltd.
Agent:
Anton Hutter, Venner Shipley LLP
Status:
GRANT OF PATENT INTENDED
EP11850226

QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS

IPC classification:
A61K 31/496, A61K 31/4709, A61K 31/4375, A61P 11/00, A61K 31/47, C07D 491/107, C07D 471/04, C07D 405/12, C07D 401/12, C07D 401/06, C07D 215/48, C07D 401/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP16205393

ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1

IPC classification:
A61P 35/00, A61K 39/395, C07K 16/28
Applicant:
Merck Sharp & Dohme Ltd.
Agent:
James Michael Frederic Horgan, Merck Sharp & Dohme Ltd.
Status:
The application has been published

Please Sign in to use this feature